Key result
Drug-eluting stents significantly reduce in-stent restenosis and target vessel revascularization compared to bare metal stents, though concerns remain regarding late stent thrombosis and high costs.
Why the study?
Does drug-eluting stents reduce in-stent restenosis and target vessel revascularisation compared to bare metal stents in patients undergoing percutaneous coronary intervention?
Population
Patients undergoing percutaneous coronary intervention (PCI) for coronary artery disease
Comparison
Drug-eluting stents, including sirolimus-eluting… vs Bare metal stents (BMS)
Design
Review
Authors
Loading...
Supports DES over BMS to reduce restenosis in PCI; leaves open long-term thrombosis and cost questions.
Does drug-eluting stents reduce in-stent restenosis and target vessel revascularisation compared to bare metal stents in patients undergoing percutaneous coronary intervention?
While drug-eluting stents represent a major advancement by markedly reducing in-stent restenosis compared to bare metal stents, their long-term safety, efficacy in complex lesions, and economic impact require ongoing evaluation.
Wong et al. (2004) conducted a review in Coronary artery disease (In-stent restenosis). Drug-eluting stents (Sirolimus and Paclitaxel) vs. Bare metal stents was evaluated. Drug-eluting stents significantly reduce in-stent restenosis and target vessel revascularization compared to bare metal stents, though concerns remain regarding late stent thrombosis and high costs.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: